Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at…

Overview of attention for article published in Clinical Drug Investigation, May 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 65 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 825 followers.

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. https://t.co

15 May 2018

Reply Repost Favourite